婷婷丁香五月激情综合在线,国产色诱美女免费视频,美女av在线,欧洲美女粗暴牲交免费

服務熱線

15021010459
產品中心
當前位置:主頁 > 產品中心 > 其他 > HES >Hospira 6% Hetastarch in 0.9% Sodium Chloride Inje

Hospira 6% Hetastarch in 0.9% Sodium Chloride Inje

簡要描述:6% Hetastarch in 0.9% Sodium Chloride Injection
代血漿

  • 產品型號:0409-7248-03
  • 廠商性質:代理商
  • 更新時間:2018-02-12
  • 訪  問  量:2623
詳細介紹

6% HETASTARCH
in 0.9% Sodium Chloride Injection
For intravenous use only

EACH 100 mL CONTAINS HETASTARCH, 6 g AND SODIUM
CHLORIDE 0.9 g IN WATER FOR INJECTION. MAY CONTAIN
SODIUM HYDROXIDE FOR pH ADJUSTMENT. ELECTROLYTES
(mEq/L): SODIUM 154, CHLORIDE 154. 308 mOsmol/LITER
(calc). pH 5.5 (3.5 TO 7.0).
IF ADMINISTRATION IS BY PRESSURE INFUSION, ALL AIR
SHOULD BE WITHDRAWN OR EXPELLED FROM THE BAG
THROUGH THE MEDICATION PORT PRIOR TO INFUSION.
STERILE, NONPYROGENIC. SINGLE-DOSE CONTAINER. 
DISCARD UNUSED PORTION. USE ONLY IF SOLUTION IS
CLEAR. USUAL DOSAGE: SEE INSERT. STORE AT 20 TO 25°C
(68 TO 77°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]
PROTECT FROM FREEZING. SEE INSERT.
DO NOT INTRODUCE ADDITIVES INTO THIS CONTAINER
Rx ONLY

AVAILABILITY

Out of Stock: 0409-7248-03Additional Information:  See below for more information regarding specific products. View additional information and potential alternatives.

ClassPlasma Volume Expander

Generic Name6% Hetastarch in 0.9% Sodium Chloride Injection

Brand Name EquivalentHespan


NDC NumberStrengthTotal VolumeProduct ImageContainer TypeCap ColorNon-DEHPLatex InformationPreservative-FreeOrder SizeProduct Information












0409-7248-03
500 mL6% Hetastarch in 0.9% Sodium Chloride InjectionFlexible ContainerN/A
YesYes1 Case (12) 













現貨供應,歡迎訂購,:  

重慶市華雅干細胞技術有限公司

 


產品咨詢

留言框

  • 產品:

  • 您的單位:

  • 您的姓名:

  • 聯系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結果(填寫阿拉伯數字),如:三加四=7
推薦產品

2024 版權所有 © 重慶市華雅干細胞技術有限公司  備案號:渝ICP備14000349號-4 sitemap.xml 管理登陸 技術支持:化工儀器網

地址:重慶市江北區(qū)金渝大道153號8棟20-14 傳真:023-63419626 郵件:sales@ys-bio.com

重慶市華雅干細胞技術有限公司主要經營干細胞研究 干細胞治療產品 生物試劑 實驗耗材 藥物研發(fā)等產品。

關注我們

服務熱線

400-021-2200

掃一掃,關注我們